Remed Co.Ltd (302550) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Remed Co.Ltd (302550) has a cash flow conversion efficiency ratio of 0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.01 Billion ≈ $684.70K USD) by net assets (₩39.46 Billion ≈ $26.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Remed Co.Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Remed Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 302550 liabilities breakdown for a breakdown of total debt and financial obligations.
Remed Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Remed Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MGB Bhd
KLSE:7595
|
-0.059x |
|
Ardiden Ltd
AU:ADV
|
-0.008x |
|
TAPEX INC
KO:055490
|
0.003x |
|
Asia File Corporation Bhd
KLSE:7129
|
0.035x |
|
Formosa Prosonic Industries
KLSE:9172
|
0.009x |
|
Quest For Growth - Pricaf
BR:QFG
|
-0.014x |
|
Evergreen Corp
NASDAQ:EVGR
|
-0.024x |
|
ad pepper media International N.V
XETRA:APM
|
0.095x |
Annual Cash Flow Conversion Efficiency for Remed Co.Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Remed Co.Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Remed Co.Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩39.46 Billion ≈ $26.74 Million |
₩2.40 Billion ≈ $1.62 Million |
0.061x | +96.37% |
| 2024-12-31 | ₩40.25 Billion ≈ $27.28 Million |
₩1.24 Billion ≈ $843.40K |
0.031x | -72.79% |
| 2023-12-31 | ₩30.79 Billion ≈ $20.87 Million |
₩3.50 Billion ≈ $2.37 Million |
0.114x | -34.77% |
| 2022-12-31 | ₩29.92 Billion ≈ $20.28 Million |
₩5.21 Billion ≈ $3.53 Million |
0.174x | +230.28% |
| 2021-12-31 | ₩26.10 Billion ≈ $17.69 Million |
₩-3.49 Billion ≈ $-2.36 Million |
-0.134x | -227.93% |
| 2020-12-31 | ₩24.79 Billion ≈ $16.80 Million |
₩2.59 Billion ≈ $1.76 Million |
0.105x | -20.14% |
| 2019-12-31 | ₩24.62 Billion ≈ $16.69 Million |
₩3.22 Billion ≈ $2.18 Million |
0.131x | +550.48% |
| 2018-12-31 | ₩10.94 Billion ≈ $7.42 Million |
₩-317.96 Million ≈ $-215.48K |
-0.029x | -282.16% |
| 2017-12-31 | ₩4.19 Billion ≈ $2.84 Million |
₩66.75 Million ≈ $45.24K |
0.016x | -- |
About Remed Co.Ltd
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells,… Read more